Cancer immunotherapies
by design™
iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for patients.
At iTeos, we are specializing in targeted immunotherapies for people living with cancer.
We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies.
Our two clinical stage programs, EOS-448 and Inupadenant, were designed with the aim of having best-in-class properties. We are moving rapidly into late stage clinical trials to explore the full potential of our science.
Our pipeline
Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.
Preclinical
Phase 1
Phase 2a
Randomized
Registration-directed
EOS-448
+ dostarlimab | Solid Tumors
Phase 1, dosing
+ dostarlimab | 1L NSCLC PDL1 high
Registration-directed, non-dosing
+ dostarlimab | HNSCC
Registration-directed, non-dosing
+ dostarlimab | Undisclosed
Registration-directed, non-dosing
+ dostarlimab + CD96 | Solid Tumors
Phase 1, non-dosing
+ dostarlimab + Inupadenant | Solid Tumors
Phase 1, non-dosing
+ Inupadenant | PD-1 Resistant Melanoma
Phase 1, dosing
Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma
Phase 2a, dosing
Inupadenant
Monotherapy | Evaluating Patient and Indication Selection Biomarkers
Phase 2, dosing
+ pembrolizumab | PD-1 Resistant Melanoma
Phase 2, dosing
+ chemotherapy | Post-IO mNSCLC
Randomized, non-dosing
EOS-984
IND Enabling Studies
Preclinical, dosing
Studies with dark backgrounds are dosing patients. Studies with light backgrounds have not yet dosed patients.
There has never been a better time to work at iTeos.
As a leading clinical-stage biotech, our innovative science-driven work is fascinating and potentially lifesaving.
Whether it is working in our laboratory or in our offices, you will help people live healthier lives. You will find yourself on the forefront of science, within a high-tech environment where no two days are the same.
Latest press releases
iTeos Reports First Quarter 2022 Financial Results and Provides Business Update
Enrolling patients with multiple myeloma in clinical trial of anti-TIGIT monoclonal antibody, EOS-448/GSK4428859A in monotherapy and in combination with BMS’s…
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the …
Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first evidence of a treatment effect…
